Northridge, CANCT07684820Now EnrollingIRB Ready

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial in Northridge, CA

Access cutting-edge chronic obstructive pulmonary disease (copd) treatment through this clinical trial at a research site in Northridge. Study-provided care at no cost to qualified participants.

Sponsored by Expedition Therapeutics, Inc

Quick Self-Assessment

See if you qualify for this Northridge location

Preparing your pre-screening questions…

Expert Care in Northridge

Access chronic obstructive pulmonary disease (copd) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic obstructive pulmonary disease (copd) treatment provided free

Apply for This Northridge Location

Check if you qualify for this chronic obstructive pulmonary disease (copd) clinical trial in Northridge, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Northridge

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Northridge site if eligible
  4. 4Begin participation

About This Chronic Obstructive Pulmonary Disease (COPD) Study in Northridge

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

Sponsor: Expedition Therapeutics, Inc

Who Can Participate

Inclusion Criteria

Provided written informed consent for the study
Body mass index (BMI) ≥ 18.5 kg/m2 and \< 35 kg/m2 at screening (weight ≥ 50 kg for males and ≥ 45 kg for females)
Diagnosis of COPD for at least 1 year
COPD with physician-confirmed diagnosis of chronic bronchitis (persistent, productive cough and sputum for at least 3 months in the past year)
At least 2 moderate or \> 1 severe exacerbation within 12 months prior to screening
Current or ex-tobacco smokers with history of ≥ 10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year);
Stable maintenance therapy with either dual or triple inhaled therapy for ≥ 3 months prior to enrollment per below:
Dual therapy: long-acting beta-2 agonist/muscarinic antagonist (LABA/LAMA) or inhaled corticosteroids (ICS)/LAMA, or ICS/LABA OR
Triple therapy: ICS/LAMA/LABA
Post-BD FEV1/FVC \< 0.7 and post-BD FEV1(% predicted) ≥ 40% at Screening
COPD Assessment Test (CAT) score ≥ 10 at Screening
If participant is of childbearing potential, must commit to practicing highly effective methods of birth control and not donating eggs during the study and at least 14 days after the last dose.
Male participants commit to the following during the study and for at least 14 days after the last dose:
Practice true sexual abstinence (refrain from heterosexual intercourse)
Use a condom with any female partner of childbearing potential and ensure that the partner uses a highly effective contraceptive method (eg, IUD/IUS, combined hormonal contraception, progestogen-only contraception, or bilateral tubal occlusion).
Be vasectomized (≥ 3 months prior to screening)
Refrain from donating sperm during the Treatment Period and for at least 14 days after the last dose of the IP

Exclusion Criteria

COPD exacerbation within the 4 weeks prior to randomization.
Clinically important pulmonary disease other than COPD (eg, asthma, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, tuberculosis).
Significant immunodeficiency and/or positive serological tests for hepatitis B, hepatitis C, or known human immunodeficiency virus (HIV) infection.
Pneumonia requiring antibiotics or antiviral medication within 28 days prior to Visit 1.
History of clinically significant infection (excluding pneumonia), acute upper or lower respiratory infection, requiring antibiotics or antiviral medication within 14 days prior to Visit 1.
Evidence of active liver disease (with or without ongoing treatment)
Participants with a QT interval, from the ECG conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) \> 450 msec (or QTcF \> 480 msec in participants with bundle branch block).
Current or history, within the past year of Visit 1, of substance and/or alcohol abuse.
History of cancer except:
Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1
Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1
Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during Screening Period, which in the opinion of the investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
Known history of allergy or reaction to any component of the investigational product formulation
Current treatment with biologic drugs for COPD (eg, dupilumab, mepolizumab) or use of Therapeutics, biologics within 5 half-lives or 4 months, whichever is longer, from randomization
Current long-term treatment with oxygen therapy \> 12 hours per day
Use of immunoglobulin or blood products in 30 days prior to Screening
Received a live attenuated vaccine within 30 days prior to Screening
Participants who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation \< 4 weeks prior to screening (Note: participants in the maintenance phase of a rehabilitation program can be included).
History or active conditions associated with the onset of non-hereditary palmoplantar keratosis:
Have any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study
Has active periodontal disease and are either:
Currently treated by a dentist for this condition or
Expected to have periodontal disease-related procedures within the study period
Are scheduled to have tooth extraction that will occur during the study period

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Northridge?

Yes, this clinical trial (NCT07684820) has an active research site in Northridge, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Options in Northridge, CA

If you're searching for chronic obstructive pulmonary disease (copd) treatment options in Northridge, CA, this clinical trial (NCT07684820) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Northridge research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic obstructive pulmonary disease (copd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic obstructive pulmonary disease (copd) clinical trials near you to find additional studies recruiting in your area.

More Parkinsons Disease Trials in Northridge, CA

See all parkinsons disease clinical trials recruiting in Northridge — not just this study.

Browse Parkinsons Disease Trials in Northridge →

Browse More Trials by Condition

Parkinsons Disease TrialsUlcerative Colitis TrialsAnkylosing Spondylitis TrialsCOPD TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Northridge?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Northridge, CA